Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
An open label, single centre, single arm, prospective feasibility study evaluating the effectiveness of near-infrared fluorescence(NIRF)using indo-cyanine green(ICG)in intra-abdominal or intra-thoracic minimally invasive surgery(MIS)in paediatric oncology.
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes